ArticleTranslational cancer research2026
Immune-driven induction of miR-501-5p by IL-17A enhances colorectal cancer progression.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Colorectal cancer (CRC) patients are more susceptible to infections due to immune dysregulation. The interleukin-17A (IL-17A) signaling pathway plays a critical role in both immune defense and cancer metastasis. This study aimed to identify novel microRNAs (miRNAs) involved in IL-17A-mediated CRC progression. Methods: RNA sequencing (RNA-seq) was used to analyze gene expression in stimulated peripheral blood mononuclear cells (PBMCs) and HCT116 cells cultured with their conditioned media (CM). Candidate miRNAs involved in IL-17A or transforming growth factor-β (TGF-β)-driven CRC progression were evaluated by reverse transcription quantitative real-time polymerase chain reaction (RT-qPCR), western blotting, and wound healing assays. Prognostic relevance was assessed in The Cancer Genome Atlas colon adenocarcinoma (TCGA-COAD) cohort via Cox regression and Kaplan-Meier survival analysis. Results: IL-17 signaling emerged as one of the most significantly enriched pathways following immune stimulation. Both IL-17A and TGF-β upregulated the epithelial-mesenchymal transition (EMT) marker vimentin and promoted CRC cell migration. Among the five candidate miRNAs identified, miR-501-5p was markedly induced by IL-17A and TGF-β. Functional assays revealed that either transient overexpression or inhibition of miR-501-5p significantly altered CRC cell migration in response to IL-17A. Notably, elevated miR-501 expression was associated with more than a twofold increased risk of death in stage IV CRC patients from the TCGA-COAD cohort. Conclusions: IL-17 signaling may drive CRC progression and poor clinical outcomes in part through the induction of miR-501-5p, underscoring its potential role in immune-related cancer metastasis and as a prognostic biomarker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.